Individualized therapy to prevent bone mineral density loss after kidney and kidney-pancreas transplantation.
نویسندگان
چکیده
BACKGROUND AND OBJECTIVES Most patients who undergo kidney or kidney-pancreas transplantation have renal osteodystrophy, and immediately after transplantation bone mineral density (BMD) commonly falls. Together, these abnormalities predispose to an increased fracture incidence. Bisphosphonate or calcitriol therapy can preserve BMD after transplantation, but although bisphosphonates may be more effective, they pose potential risks for adynamic bone. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS A total of 153 kidney (61%) and kidney-pancreas (39%) transplant recipients were allocated to bisphosphonate (62%) or calcitriol (38%) therapy using an algorithm that incorporated BMD, prevalent vertebral fracture, biomarkers of bone turnover, and risk factor assessment. Patients received cholecalciferol and calcium as appropriate and were followed for 12 mo. RESULTS Patients who were treated with bisphosphonates had lower BMD at the lumbar spine and femoral neck and longer time on dialysis. Age and gender were similar between the groups. At 12 mo, bisphosphonate-treated patients had significant BMD increases at the lumber spine and femoral neck and a negative trend at the wrist. Patients who were allocated to calcitriol, who were assessed to have lower baseline fracture risk, had no significant change in BMD at any site. At 1 yr, mean levels of bone turnover marker and intact parathyroid hormone normalized in both groups. Incident fracture rates did not differ significantly. CONCLUSIONS With targeted treatment, BMD levels were stable or improved and bone turnover markers normalized. This algorithm provides a guide to targeting therapy after transplantation that avoids BMD loss and may reduce suppression of bone turnover.
منابع مشابه
تاثیر 12هفته تمرینات مقاومتی بر تراکم استخوانی در بیماران پیوند کلیوی
Loss of bone density is one of the most common side effects in kidney transplant patients. Regarding the role of physical activity and exercise in preventing bone loss bone density, The purpose of this study was to examine the effects of 12 weeks of resistance training on the bone density in renal transplant patients. Methods A quasi-experimental study was designed for this research. A total...
متن کاملOsteoporosis after stem cell transplantation
Background Stem cell transplantation has become as a novel treatment for end-stage kidney, lung, heart , liver diseases and several hematologic disorders. Improved survival of transplant recipients has raised awareness of post-transplant complications. One of these complications is transplant-related osteoporosis. Methods In this manuscript we review prevention methods for transplant-relat...
متن کاملCKD-mineral and bone disorder management in kidney transplant recipients.
Kidney transplantation, the most effective treatment for the metabolic abnormalities of chronic kidney disease (CKD), only partially corrects CKD-mineral and bone disorders. Posttransplantation bone disease, one of the major complications of kidney transplantation, is characterized by accelerated loss of bone mineral density and increased risk of fractures and osteonecrosis. The pathogenesis of...
متن کاملIs management of angiomyolipoma different after kidney transplantation?
mineral density changes within six months of renal transplantation. increased bone turnover and low bone density in long-term survivors to kidney transplantation. Posttransplant bone disease: evidence for a high bone resorption state. mineral density in kidney transplant recipients and patients on hemodialysis: a comparison with healthy individuals. Comparison of alendronate and pamidronate on ...
متن کاملComparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation.
INTRODUCTION Osteoporosis develops and progresses in a considerable number of kidney transplant patients. Bisphosphonates, which are used for prevention and treatment of osteoporosis, may accentuate gasterointestinal complications and lead to more nonadherence to treatment. This randomized clinical trial was conducted to compare the effect of pamidronate versus alendronate on early bone mineral...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical journal of the American Society of Nephrology : CJASN
دوره 5 1 شماره
صفحات -
تاریخ انتشار 2010